Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 393 results for heart failure

  1. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (IPG805)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  2. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.

  3. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

  4. NICE training and development opportunities

    Training and development opportunities at NICE

  5. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  6. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  7. Chronic heart failure in adults: management (CG108)

    This guideline has been updated and replaced by NICE guideline NG106.

  8. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.

  9. Percutaneous laser coronary angioplasty (IPG378)

    Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.

  10. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  11. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

    Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).

  12. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

  13. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  14. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.